Stock Ratings / Health Care / IXHL / forecast

FLNA (47) IBO (34) AARD (37) ACET (36) ⌘ Pro Terminal →

Incannex Healthcare Inc. (IXHL) 12-Month Stock Forecast & Price Target Cone

Q: What is IXHL's 12-month stock price target?

Incannex Healthcare Inc. (IXHL) carries a 12-month consensus base price target of $2.36 (-8.5% from $2.58), with a bull-case target of $15.66 and a bear-case floor of $1.84.

Q: Is IXHL stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates IXHL D- (Sell — SELL) with an RQD Confidence score of 39/100.

$2.58 -4.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Incannex Healthcare Inc. (IXHL) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $32.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IXHL)Realized 20D OHLCV Swing Band: ±10%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your IXHL Position Size: $10,000

Shares at $2.58: 3876.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $1.84

$7,132

$-2,868 (-28.7%)

12M Consensus BaseTarget $2.36

$9,147

$-853 (-8.5%)

12M Bull Case BreakoutTarget $15.66

$60,698

+$50,698 (+507.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$2	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$15	69%	B
JP MorganUS Large-Cap Research	SELL	$2	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IXHL)

✓Walkthrough of IXHL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IXHL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.23%▼ DESCENDING CHANNEL

2026-10-30O $2.58H $2.62L $2.50C $2.58VOL 102.5K

RES: $3.66SUP: $2.20SMA50: $3.18SMA200: $4.20

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IXHL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IXHL Butterfly Map → + Track IXHL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IXHL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IXHL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IXHL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IXHL)

Health Care Rank #681 of 1016 ⚔️ FLNA vs IXHL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IXHL vs. FLNA, IBO, AARD, ACET)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Incannex Healthcare Inc. (IXHL) ranks #681 by composite RQD confidence (39/100, grade D-) and #795 by equity capitalization ($32.4M). Within this direct 5-issuer industry benchmark cohort, IXHL leads on earnings valuation at N/A trailing P/E, while IBO leads on capital efficiency and profitability with -27.5% ROIC and -30.0% gross margin. FLNA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with IXHL at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IXHL ACTIVE Incannex Healthcare Inc.	D-	39/100	—	—	-35.0%	-4.80%	$32.4M	Benchmark Subject
FLNA Filana Therapeutics Inc.	D	47/100	—	—	-35.0%	+1.12%	$31.8M	/flna-vs-ixhl →
IBO Impact BioMedical Inc.	E	34/100	—	-30.0%	-27.5%	-3.00%	$33.1M	/ibo-vs-ixhl →
AARD Aardvark Therapeutics Inc.	D-	37/100	—	—	-35.0%	-4.64%	$31.5M	/aard-vs-ixhl →
ACET Adicet Bio Inc.	D-	36/100	—	—	-35.0%	-6.04%	$33.5M	/acet-vs-ixhl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001873875

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Incannex Healthcare Inc. (IXHL) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $12.0K ) , GAAP net income of -$46.9M, operating cash flow of -$12.5M, and free cash flow of -$12.5M (+22.3% YoY). On the balance sheet, IXHL closed FY2025 with $75.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$0	-$46.9M	-$12.5M	-$12.5M	$75.0M	—
FY2024 (FY)	2024-06-30	$12.0K	-$18.5M	-$15.8M	-$16.1M	$11.1M	$2.4M
FY2023 (FY)	2023-06-30	$0	-$48.8M	-$10.7M	-$10.7M	—	—

3. IXHL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IXHL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Incannex Healthcare Inc. (NASDAQ: IXHL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $2.58 (-4.80% 1D, market cap $32.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, IXHL ranks #681 in composite RQD confidence.

How does IXHL compare to FLNA and IBO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IXHL carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FLNA (Filana Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $31.8M) and IBO (Impact BioMedical Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -27.5%, cap $33.1M). Among the 5-stock peer group, IXHL leads on earnings multiple (N/A) while IBO leads on capital efficiency (-27.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IXHL?

Per IXHL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001873875), Incannex Healthcare Inc. generated $0 in revenue (-100.0% YoY), -$46.9M in net income, and -$12.5M in free cash flow against $75.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IXHL trading relative to its 50-day, 200-day, and 52-week technical levels?

IXHL last traded at $2.58 (-4.80% on volume of 56,910 shares), positioning the stock -18.87% below its 50-day simple moving average ($3.18) and -38.57% below its 200-day simple moving average ($4.20). Across its 52-week range of $2.49 to $14.91, IXHL sits at the 0.7% percentile with a 14-day RSI of 29.0 (OVERSOLD (<32)) and an implied next-earnings move of ±10.0% ($2.32 to $2.84).

IXHL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is IXHL's 12-month stock price target?

Incannex Healthcare Inc. (IXHL) carries a 12-month consensus base price target of $2.36 (-8.5% from $2.58), with a bull-case target of $15.66 and a bear-case floor of $1.84.

Is IXHL stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates IXHL D- (Sell — SELL) with an RQD Confidence score of 39/100.

Direct Sub-Reports: IXHL RQD Cockpit IXHL 12M Forecast IXHL Earnings & Move IXHL Dividends & DRIP IXHL Insiders & 13F IXHL Whale Options IXHL Profit Sankey IXHL News & Why